Arcturus Capital

Arcturus Therapeutics is a clinical-stage messenger RNA (mRNA) medicines company focused on the development of infectious disease vaccines and therapies for rare liver and respiratory diseases. The company leverages its proprietary LUNAR lipid-mediated delivery platform and STARR self-amplifying mRNA technology to create a diverse pipeline of candidates. Its lead product, a COVID-19 vaccine (Kostaive), has received regulatory approval in Japan, marking a significant milestone for its self-amplifying mRNA platform. Arcturus also advances programs for ornithine transcarbamylase (OTC) deficiency and cystic fibrosis, supported by strategic partnerships with global leaders such as CSL Seqirus and Meiji Seika Pharma.